Skip to main content
Premium Trial:

Request an Annual Quote

Paul Schimmel, Christoph Westphal, Raj Parekh, Wilson Totten, Amit Kumar, and Naveen Anand

Premium

Biotechnology startup Sirtris Pharmaceuticals said last week that Paul Schimmel and Christoph Westphal have joined its board of directors.

Schimmel is a faculty member of the Scripps Institute, a member of the National Academy of Sciences, and a cofounder of Alnylam Pharmaceuticals. He holds a PhD from the Massachusetts Institute of Technology.

Westphal is a general partner at the venture capital firm of Polaris Venture Partners and CEO of Sirtris. He is also a cofounder, and was the startup CEO, of Alnylam. Westphal holds a PhD and MD from Harvard Medical School.


Galapagos Genomics has appointed Raj Parekh as chairman, and Wilson Totten as a director.

Parekh is currently Entrepreneur in Residence at Abingworth, a UK-based venture capital company. He co-founded Oxford GlycoSciences in 1988 and was chief scientific officer and senior vice president of research.

Totten is CEO of ProStrakan, a company formed by the recent merger of Strakan and Proskelia. Until recently, he was R&D director at Shire. Before joining Shire, in 1998, he was vice president of clinical R&D with Astra Charnwood.


CombiMatrix president and CEO Amit Kumar will become a director of start-up drug maker Leuchemix.

CombiMatrix, a unit of Acacia Research, earlier this week said it will pay Leuchemix $4 million over two years to obtain a 33-percent stake in the company.


Hybridon has appointed Naveen Anand as the company’s vice president of corporate and business development.

Anand was previously vice president of business development at Shire Biologics. Before this, he was vice president of business development and licensing at Procyon Biopharma.

Anand holds a PhD in natural sciences from the University of Cambridge and an MBA from the University of Toronto, Canada.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.